Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Nakamura R, et al. Among authors: yano s. Cancer Lett. 2024 Aug 28;598:217124. doi: 10.1016/j.canlet.2024.217124. Epub 2024 Jul 24. Cancer Lett. 2024. PMID: 39059573 Free article.
Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis.
Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Taniguchi Y, Morinaga S, Sone T, Okuda M, Matsumoto I, Yano S, Tsuchiya H. Asano Y, et al. Among authors: yano s. Cancer Med. 2023 Jun;12(11):12425-12437. doi: 10.1002/cam4.5952. Epub 2023 Apr 19. Cancer Med. 2023. PMID: 37076988 Free PMC article.
Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series.
Koba H, Yoneda T, Morita H, Kimura H, Murase Y, Terada N, Tambo Y, Horie M, Kasahara K, Matsumoto I, Yano S. Koba H, et al. Among authors: yano s. Thorac Cancer. 2024 Mar;15(8):661-666. doi: 10.1111/1759-7714.15241. Epub 2024 Feb 7. Thorac Cancer. 2024. PMID: 38323355 Free PMC article.
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, Tachibana Y, Matsui Y, Nakamura R, Ishida M, Kawachi H, Kunimasa K, Sasaki T, Nishida M, Furuya N, Watanabe S, Shiotsu S, Nishioka N, Horinaka M, Sakai T, Uehara H, Yano S, Son BK, Tokuda S, Takayama K. Morimoto K, et al. Among authors: yano s. Cancer Lett. 2024 Apr 10;587:216692. doi: 10.1016/j.canlet.2024.216692. Epub 2024 Feb 9. Cancer Lett. 2024. PMID: 38342232 Free article.
Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study.
Nagai H, Shimada T, Takahashi Y, Nishikawa M, Tozuka H, Yamamoto Y, Niwa O, Takahara Y, Fujita A, Nagase K, Kasahara K, Yano S, Sai Y. Nagai H, et al. Among authors: yano s. J Pharm Health Care Sci. 2022 Dec 1;8(1):28. doi: 10.1186/s40780-022-00258-7. J Pharm Health Care Sci. 2022. PMID: 36451213 Free PMC article.
Epidemiological and Therapeutic Analyses in Lung Cancer Patients Over 80 Years Old in the Hokushin Region: A Retrospective Hospital Administrative Database Study.
Koizumi T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Tanaka Y, Tomita R, Araki T, Hayashi R, Yasumoto K, Uramoto H, Hirono Y, Makino T, Nakada M, Yano S. Koizumi T, et al. Among authors: yano s. Clin Lung Cancer. 2023 Mar;24(2):145-152. doi: 10.1016/j.cllc.2022.12.001. Epub 2022 Dec 31. Clin Lung Cancer. 2023. PMID: 36639281 Free article.
Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR.
Ishibashi K, Ichinose T, Kadokawa R, Mizutani R, Iwabuchi S, Togi S, Ura H, Tange S, Shinjo K, Nakayama J, Nanjo S, Niida Y, Kondo Y, Hashimoto S, Sahai E, Yano S, Nakada M, Hirata E. Ishibashi K, et al. Among authors: yano s. Dev Cell. 2024 Mar 11;59(5):579-594.e6. doi: 10.1016/j.devcel.2024.01.010. Epub 2024 Feb 2. Dev Cell. 2024. PMID: 38309264
2,528 results